PMID- 33803190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230919
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 14
IP  - 3
DP  - 2021 Mar 9
TI  - The Role of Galcanezumab in Migraine Prevention: Existing Data and Future 
      Directions.
LID - 10.3390/ph14030245 [doi]
LID - 245
AB  - Galcanezumab is a humanized monoclonal antibody blocking the calcitonin 
      gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 
      randomized placebo-controlled clinical trials showed that galcanezumab is 
      superior to placebo in reducing migraine headaches, migraine-specific quality of 
      life, and headache-related disability. Most of the adverse events (AEs) were mild 
      to moderate and did not affect trial completion rates significantly. Along with 
      erenumab, fremanezumab, and eptinezumab, galcanezumab forms a novel class of 
      anti-migraine preventative treatments that is disease-specific and 
      mechanism-based, unlike the standard ones. In addition, galcanezumab has also 
      been shown to be effective in cluster headache, though more clinical trials are 
      required. Overall, galcanezumab is a promising emerging treatment in migraine 
      prophylaxis. However, it needs to be tested in larger clinical trials focused on 
      treatment-resistant migraine. Furthermore, its safety profile, especially its 
      potential association with an increased cardiovascular risk, needs to be 
      established through long-term, real-world data. This review aims to give an 
      overview of its pharmacological properties as well as to report and discuss data 
      from clinical trials and its potential place in headache therapeutics.
FAU - Gklinos, Panagiotis
AU  - Gklinos P
AUID- ORCID: 0000-0001-5022-6460
AD  - Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece.
FAU - Mitsikostas, Dimos D
AU  - Mitsikostas DD
AD  - 1st Neurology Department, Aeginition Hospital, National and Kapodistrian 
      University of Athens, 11521 Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210309
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC7998387
OTO - NOTNLM
OT  - galcanezumab
OT  - migraine
OT  - migraine prevention
OT  - monoclonal antibodies
OT  - review
COIS- P.G. reports no disclosures. D.D.M. has received consulting, speaking fees and 
      travel grants from Allergan, Amgen, Bayer, Biogen, Cefaly, Genesis Pharma, 
      GlaxoSmithKline, ElectroCore, Eli Lilly, Merck-Serono, Merz, Mylan, Novartis, 
      Roche, Sanofi- Genzyme, Specifar and Teva.
EDAT- 2021/04/04 06:00
MHDA- 2021/04/04 06:01
PMCR- 2021/03/09
CRDT- 2021/04/03 01:13
PHST- 2021/02/21 00:00 [received]
PHST- 2021/03/04 00:00 [revised]
PHST- 2021/03/06 00:00 [accepted]
PHST- 2021/04/03 01:13 [entrez]
PHST- 2021/04/04 06:00 [pubmed]
PHST- 2021/04/04 06:01 [medline]
PHST- 2021/03/09 00:00 [pmc-release]
AID - ph14030245 [pii]
AID - pharmaceuticals-14-00245 [pii]
AID - 10.3390/ph14030245 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2021 Mar 9;14(3):245. doi: 10.3390/ph14030245.